Sézary cell count (peripheral blood, B-classification per ISCL/EORTC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-SEZARY-COUNT |
|---|---|
| Type | Biomarker |
| Aliases | Sézary cell countПідрахунок клітин Сезарі (периферична кров, B-класифікація за ISCL/EORTC) |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | cell_count |
|---|---|
| Measurement | MethodFlow cytometry (CD4+CD7- or CD4+CD26- abnormal subset) + morphology (atypical lymphocytes with cerebriform nuclei) Unitscells/μL or % of CD4+; B0 <250 / B1 250-1000 / B2 ≥1000 OR ≥5% Sézary by morphology |
| Related biomarkers | None declared |
Notes
Defines "B" component of TNMB staging in MF/Sézary. B2 (≥1000 Sézary cells/μL) is the leukemic stage = Sézary syndrome by definition; up- stages disease to IVA1 regardless of skin stage. Qualifies for systemic-first therapy and especially for mogamulizumab (highest efficacy in B2). Distinguished from reactive lymphocytosis by clonal TCR (TEST-TCR-CLONALITY) + aberrant flow phenotype.
Used By
Red flag
RF-MF-SEZARY-LEUKEMIC- MF with B2 blood involvement (Sézary cell count ≥1000/μL OR ≥5% Sézary by morphology) — d...